|
Index of reports
> Cases with Nausea (171)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include nausea. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 171 Next >>
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Prednisone
Dosage: 2.5 mg/day
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20
Patient:
Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Epirubicin
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Herceptin
Dosage: loading dose
Indication: Breast Cancer
Herceptin
Dosage: maintenance dose
Lapatinib
Dosage: arm b
Administration route: Oral
Indication: Breast Cancer
Lapatinib
Dosage: arm c
Administration route: Oral
Paclitaxel
Indication: Breast Cancer
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 2.5 mg/day
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 2.5 mg/day
Possible Cyclophosphamide side effects in female
Reported by a physician from United States on 2012-08-16
Patient: female
Reactions: Abdominal Pain, Vomiting, Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Peripheral Sensory Neuropathy, Constipation, Fatigue, Diarrhoea, Neutropenia
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: cycle 3
Adriamycin PFS
Dosage: cycle 4
Adriamycin PFS
Dosage: cycle 2
Adriamycin PFS
Dosage: cycle 1
Indication: Breast Cancer
Cyclophosphamide
Dosage: cycle 4
Cyclophosphamide
Dosage: cycle 3
Indication: Breast Cancer
Cyclophosphamide
Dosage: cycle 1
Cyclophosphamide
Dosage: cycle 2
Docetaxel
Dosage: cycle 4
Docetaxel
Dosage: cycle 3
Indication: Breast Cancer
Docetaxel
Dosage: cycle 2
Docetaxel
Dosage: cycle 1
Doxorubicin Hydrochloride
Dosage: cycle 3
Doxorubicin Hydrochloride
Dosage: cycle 4
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: cycle 1
Doxorubicin Hydrochloride
Dosage: cycle 2
NOV-002
NOV-002
Dosage: administered approximately 3 hr apart
Indication: Breast Cancer
NOV-002
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Cyclophosphamide side effects in 61 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-13
Patient: 61 year old female
Reactions: Mucosal Inflammation, Nausea, Pyrexia, Diffuse Large B-Cell Lymphoma Recurrent, Oral Herpes
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Etoposide
Indication: Diffuse Large B-Cell Lymphoma
Methotrexate
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in 65 year old female
Reported by a health professional (non-physician/pharmacist) from Sweden on 2012-08-13
Patient: 65 year old female
Reactions: Myositis, Dysphagia, Nausea, Ataxia, Hemiparesis, Hepatic Enzyme Increased, Dysarthria, Fatigue, Nystagmus, Balance Disorder, Quadriparesis, Vertigo, Arthritis, Progressive Multifocal Leukoencephalopathy
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine Sodium
Dosage: 150 mg, qd
Administration route: Oral
Cyclophosphamide
Dosage: 100 mg, qd
Administration route: Oral
Methotrexate
Dosage: 20 mg, qw
Prednisone TAB
Dosage: 40 mg, qd
Administration route: Oral
Prednisone TAB
Dosage: 17.5 mg, qd
Administration route: Oral
Prednisone TAB
Dosage: 10 mg, qd
Administration route: Oral
Prednisone TAB
Dosage: 40 mg, qd
Administration route: Oral
Prednisone TAB
Dosage: 12.5 mg, qd
Administration route: Oral
Other drugs received by patient: Methylprednisolone; Glucocorticoids; Heparin
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-08-09
Patient:
Reactions: Small Intestinal Obstruction, Vomiting, Nausea, Abdominal Pain Upper
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1340 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Doxorubicin Hydrochloride
Dosage: 90 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Prednisolone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Rituximab
Dosage: 670 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Velcade
Dosage: 2.3 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-30
End date: 2012-06-08
Vincristine
Dosage: 2 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Other drugs received by patient: Acyclovir; Allopurinol; Amitriptyline HCL; Omeprazole; Amitriptyline HCL; Metoclopramide; Metoclopramide
Possible Cyclophosphamide side effects in female
Reported by a physician from Poland on 2012-08-02
Patient: female, weighing 58.0 kg (127.6 pounds)
Reactions: Retroperitoneal Mass, Vomiting, Nausea, Anaemia, Nephropathy Toxic, Folate Deficiency, Iron Deficiency, Herpes Zoster, Vitamin B12 Increased, Asthenia, Beta 2 Microglobulin Increased, Leukopenia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Lymphoma
Start date: 2011-06-22
End date: 2011-10-27
Doxorubicin Hydrochloride
Indication: Lymphoma
Start date: 2011-06-22
End date: 2011-10-27
Prednisone
Administration route: Oral
Indication: Lymphoma
Start date: 2011-06-22
End date: 2011-10-27
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-06-22
End date: 2011-10-27
Vincristine
Indication: Lymphoma
Start date: 2011-06-22
End date: 2011-10-27
Other drugs received by patient: Heviran; Tamoxifen Citrate
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-30
Patient:
Reactions: Small Intestinal Obstruction, Vomiting, Nausea, Abdominal Pain Upper
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1340 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Doxorubicin Hydrochloride
Dosage: 90 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Prednisolone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Rituximab
Dosage: 670 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Velcade
Dosage: 2.3 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-30
End date: 2012-06-08
Vincristine
Dosage: 2 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-05-11
End date: 2012-05-30
Other drugs received by patient: Omeprazole; Metoclopramide; Amitriptyline Hydrochloride; Allopurinol; Amitriptyline Hydrochloride; Metoclopramide; Acyclovir
Possible Cyclophosphamide side effects in female
Reported by a physician from Germany on 2012-07-27
Patient: female
Reactions: Vomiting, Nausea, Hyponatraemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1027.5 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Doxorubicin Hydrochloride
Dosage: 66.5 mg, qd
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Pegfilgrastim
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-07-08
End date: 2012-07-08
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: B-Cell Lymphoma
Start date: 2012-07-03
End date: 2012-07-08
Rituximab
Dosage: 513.75 mg, qd
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Vincristine
Dosage: 2.76 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Other drugs received by patient: Allopurinol; Amlodipine Besylate; Losartan Potassium; Pantoprazole Sodium; Metoclopramide; Bisoprolol Fumarate
Possible Cyclophosphamide side effects in female
Reported by a physician from Canada on 2012-07-26
Patient: female
Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Neutropenia, Cardiotoxicity, Asthenia, Cardiac Failure Congestive
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 21 day cycle
Indication: Breast Cancer
Doxorubicin HCL
Dosage: 21 day cycle
Indication: Breast Cancer
Taxol
Dosage: with trastuzumab given weekly for 12 weeks
Indication: Breast Cancer
Trastuzumab
Dosage: first dose 4mg/kg given weekly for 12 weeks
Indication: Breast Cancer
Trastuzumab
Dosage: first dose 4mg/kg given weekly for 12 weeks
Possible Cyclophosphamide side effects in female
Reported by a physician from Germany on 2012-07-24
Patient: female
Reactions: Vomiting, Nausea
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Allopurinol
Dosage: 150 mg, qd
Start date: 2012-06-18
Cyclophosphamide
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Doxorubicin HCL
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Pegfilgrastim
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-08
End date: 2012-07-08
Prednisone
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Rituximab
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-07
End date: 2012-07-07
Vincristine
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-07-04
End date: 2012-07-04
Other drugs received by patient: Losartan Potassium; Bisoprolol Fumarate
Possible Cyclophosphamide side effects in 48 year old female
Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-23
Patient: 48 year old female
Reactions: Vomiting, Nausea, Febrile Neutropenia, Oropharyngeal Pain
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 830mg, every cycle; 800mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-27
Cyclophosphamide
Dosage: 830mg, every cycle; 800mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-06
End date: 2010-10-06
Epirubicin
Dosage: 166mg every cycle; 140mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-06
End date: 2010-10-06
Epirubicin
Dosage: 166mg every cycle; 140mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-27
Fluorouracil
Dosage: 830 mg every cycle; 700 mg, every cycle
Indication: Breast Cancer
Start date: 2010-10-06
Fluorouracil
Dosage: 830 mg every cycle; 700 mg, every cycle
Indication: Breast Cancer
Start date: 2010-10-27
Possible Cyclophosphamide side effects in female
Reported by a physician from Canada on 2012-07-20
Patient: female
Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Cardiotoxicity, Neutropenia, Asthenia, Cardiac Failure Congestive
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 21 day cycle
Indication: Breast Cancer
Doxorubicin HCL
Dosage: 21 day cycle
Indication: Breast Cancer
Taxol
Dosage: with trastuzumab given weekly for 12 weeks
Indication: Breast Cancer
Trastuzumab
Dosage: first dose 4mg/kg given weekly for 12 weeks
Indication: Breast Cancer
Trastuzumab
Dosage: first dose 4mg/kg given weekly for 12 weeks
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient:
Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 milligram/sq. meter
Indication: Multiple Myeloma
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Revlimid
Dosage: 15 milligram
Administration route: Oral
Velcade
Dosage: 1.3 milligram/sq. meter
Indication: Multiple Myeloma
Velcade
Dosage: 1.3 milligram/sq. meter
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-17
Patient:
Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole
Possible Cyclophosphamide side effects in female
Reported by a individual with unspecified qualification from United States on 2012-07-16
Patient: female, weighing 50.3 kg (110.7 pounds)
Reactions: Blood Alkaline Phosphatase Increased, Abdominal Pain, Vomiting, Nausea, Epstein-Barr Virus Test Positive, Pyrexia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1275 mg
End date: 2012-05-16
Fludarabine Phosphate
Dosage: 126 mg
End date: 2012-05-16
Rituximab (Moab C2b8 Anti Cd20, Chimeric)
Dosage: 850 mg
End date: 2012-05-14
Possible Cyclophosphamide side effects in 62 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-13
Patient: 62 year old male, weighing 66.5 kg (146.3 pounds)
Reactions: Vomiting, Nausea
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1340 mg once iv
Indication: Laryngeal Cancer
Start date: 2012-03-06
End date: 2012-03-06
Cyclophosphamide
Dosage: 1340 mg once iv
Indication: B-Cell Lymphoma
Start date: 2012-03-06
End date: 2012-03-06
Vincristine
Dosage: 2 mg once iv
Indication: B-Cell Lymphoma
Start date: 2012-03-06
End date: 2012-03-06
Vincristine
Dosage: 2 mg once iv
Indication: Laryngeal Cancer
Start date: 2012-03-06
End date: 2012-03-06
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-11
Patient: female
Reactions: Vomiting, Nausea, Alopecia, Hypertransaminasaemia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Start date: 2011-06-08
End date: 2011-07-27
Epirubicin Hydrochloride
Indication: Breast Cancer
Start date: 2011-06-08
End date: 2011-07-27
Fluorouracil
Indication: Breast Cancer
Start date: 2011-06-08
End date: 2011-07-27
Other drugs received by patient: Decadron; Kytril; Estrone W / Progesterone; Ramipril
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from United States on 2012-07-11
Patient:
Reactions: Weight Decreased, Thrombosis, Pruritus, Hypokalaemia, Fatigue, Depression, Thrombocytopenia, Alanine Aminotransferase Abnormal, Blood Antidiuretic Hormone Abnormal, Dyspnoea, Nausea, Lymphopenia, Haemoglobin Abnormal, Hyponatraemia, Febrile Neutropenia, Palmar-Plantar Erythrodysaesthesia Syndrome, Rash, Diarrhoea, Embolism, Blood Alkaline Phosphatase Abnormal, Dehydration, Neutropenia, Leukopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on days 1-14
Administration route: Oral
Indication: Breast Cancer Metastatic
Xeloda
Dosage: beginning on day 8 and continuing to day 21 (total of 14 days)
Administration route: Oral
Indication: Breast Cancer Metastatic
Possible Cyclophosphamide side effects in 28 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-11
Patient: 28 year old female
Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Gait Disturbance, Coordination Abnormal, Renal Failure Acute
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 15 units/m2 over 24h on day2
Cisplatin
Dosage: 45 mg/m2, unk
Cisplatin
Dosage: 90 mg/m2, over 4h on day1
Indication: Ovarian Cancer
Cyclophosphamide
Dosage: 750 mg/m2, unk
Cyclophosphamide
Dosage: 1000 mg/m2, over 60min on day 2
Indication: Ovarian Cancer
Doxorubicin HCL
Dosage: 30 mg/m2, unk
Doxorubicin HCL
Dosage: 45 mg/m2, over 30min on day3
Indication: Ovarian Cancer
Etoposide
Dosage: 200 mg/m2, over 2h on day3
Indication: Ovarian Cancer
Etoposide
Dosage: 100 mg/m2, unk
Vinblastine
Dosage: 6 mg/m2, over 30 minutes on day 1
Indication: Ovarian Cancer
Other drugs received by patient: Pegfilgrastim
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-10
Patient:
Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir
Possible Cyclophosphamide side effects in female
Reported by a individual with unspecified qualification from United States on 2012-07-05
Patient: female, weighing 54.0 kg (118.8 pounds)
Reactions: Abdominal Pain, Chills, Pyrexia, Dyspnoea Exertional, Feeling of Body Temperature Change, Decreased Appetite, Cough, Abdominal Pain Lower, Blood Alkaline Phosphatase Increased, Vomiting, Ultrasound Scan Abnormal, Nausea, Alanine Aminotransferase Increased, Haemoglobin Decreased, Poor Personal Hygiene, Aspartate Aminotransferase Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1275 mg cyclophosphamide (250mg/m2) over 30 minutes days 1-3 every 28 days.
End date: 2012-05-16
Fludarabine Phosphate
Dosage: 126 mg
End date: 2012-05-16
Rituximab (Moab C2b8 Anti Cd20, Chimeric)
Dosage: 850 mg
End date: 2012-05-14
Possible Cyclophosphamide side effects in 28 year old female
Reported by a individual with unspecified qualification from United States on 2012-07-05
Patient: 28 year old female
Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Peripheral Sensory Neuropathy, Paraesthesia, Neuropathy Peripheral, Coordination Abnormal, Gait Disturbance, Peripheral Motor Neuropathy, Renal Failure Acute
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 15 , units/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Cisplatin
Dosage: 90 mg/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Cyclophosphamide
Dosage: 1000 mg/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Doxorubicin (Manufacturer Unknown) (Doxorubicin) (Doxorubicin)
Dosage: 45 mg/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Etoposide
Dosage: 200 mg/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Vinblastine (Manufacturer Unknown) (Vinblastine) (Vinblastine)
Dosage: 6 mg/m2, intravenous (not otherwise specified)
Indication: Ovarian Cancer
Other drugs received by patient: Pegfilgrastim (Pegfilgrastim)
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Velcade
Dosage: on days 1 and 8
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in 28 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29
Patient: 28 year old female
Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Pancytopenia, Renal Failure Acute
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: held for cycles #5 and #6
Indication: Ovarian Cancer
Cisplatin
Dosage: reduced to 45 mg/m2
Indication: Ovarian Cancer
Cyclophosphamide
Dosage: over 60 min on day 2
Indication: Ovarian Cancer
Doxorubicin HCL
Dosage: reduced to 30 mg/m2
Indication: Ovarian Cancer
Etopophos Preservative Free
Dosage: reduced to 100 mg/m2
Indication: Ovarian Cancer
Vinblastine Sulfate
Dosage: over 30 min on day 1
Indication: Ovarian Cancer
Page 1 Next >>
|
